|
ATRX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.37949995449827E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.12569999952828E-07 |
| Normal-vs-Stage2 |
3.044400E-04 |
| Normal-vs-Stage3 |
2.0014999990714E-08 |
| Normal-vs-Stage4 |
6.05269999676139E-08 |
| Stage1-vs-Stage2 |
9.967600E-01 |
| Stage1-vs-Stage3 |
1.007440E-01 |
| Stage1-vs-Stage4 |
5.757600E-02 |
| Stage2-vs-Stage3 |
2.503400E-01 |
| Stage2-vs-Stage4 |
1.126970E-01 |
| Stage3-vs-Stage4 |
5.202200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.38750000377996E-08 |
| Normal-vs-AfricanAmerican |
3.577900E-02 |
| Normal-vs-Asian |
4.01030000000135E-05 |
| Caucasian-vs-AfricanAmerican |
1.499590E-01 |
| Caucasian-vs-Asian |
9.325200E-01 |
| AfricanAmerican-vs-Asian |
1.992240E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.56959994896044E-09 |
| Normal-vs-Female |
1.74369999994539E-07 |
| Male-vs-Female |
2.000600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.78960000005468E-06 |
| Normal-vs-Age(41-60Yrs) |
3.08680000449257E-08 |
| Normal-vs-Age(61-80Yrs) |
2.88139999971015E-07 |
| Normal-vs-Age(81-100Yrs) |
1.824290E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.776210E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.100800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.361200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.995400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.630800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.995200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.049600E-02 |
| Classical-VS-Follicular |
2.821800E-01 |
| Classical-VS-Other |
1.091160E-01 |
| Classical-VS-Normal |
7.5016000000705E-07 |
| Tall-VS-Follicular |
1.154770E-01 |
| Tall-VS-Other |
6.364600E-01 |
| Tall-VS-Normal |
1.31269999981143E-07 |
| Follicular-VS-Other |
2.781200E-01 |
| Follicular-VS-Normal |
1.66896999999055E-05 |
| Other-VS-Normal |
1.957300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.37680000020535E-08 |
| Normal-vs-N1 |
1.07230000001568E-06 |
| N0-vs-N1 |
4.170000E-01 |
|
|
